Trius Therapeutics

The lead compound from Trius, tedizolid phosphate (formerly torezolid phosphate, TR-701), successfully completed its first Phase 3 clinical trial (ESTABLISH 1) in acute skin and skin structure infections (ABSSSI).{{cite web|url=http://seekingalpha.com/article/821901-an-investment-update-on-trius-therapeutics-tedizolid|title=An Investment Update on Trius Therapeutics' Tedizolid (NYSE:MRK) | Seeking Alpha }} It is a once daily, IV and oral, oxazolidinone being developed for the treatment of serious gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).{{cite web |title=Market Close Report: NASDAQ Composite index closes at 3,807.75 up 33.41 points |url=http://www.nasdaq.com/article/trius-therapeutics-announces-data-presentations-on-tedizolid---quick-facts-20120911-01047 |website=www.nasdaq.com |publisher=Nasdaq |access-date=28 May 2023 |archive-url=https://web.archive.org/web/20131005093610/http://www.nasdaq.com/news/ |archive-date=October 5, 2013 |language=en |date=October 4, 2013}} The Phase 3 trials are being conducted under a Special Protocol Agreement with the US Food and Drug Administration and are using the draft FDA guidance of cessations of lesion spread at 48–72 hours as the primary endpoint.{{cite web|url=http://seekingalpha.com/article/821901-an-investment-update-on-trius-therapeutics-tedizolid|title=An Investment Update on Trius Therapeutics' Tedizolid (NYSE:MRK) | Seeking Alpha }} In the ESTABLISH 1 Study, 200 mg of Tedizolid given for a short course of therapy (six days) was shown to be safe, well tolerated and was as effective as the traditional length of therapy with linezolid (600 mg for ten days).{{cite web|url=http://www.fiercebiotech.com/story/trius-shares-surge-antibiotic-matches-zyvox-pivotal-phiii/2011-12-19|title=Trius shares surge as antibiotic matches Zyvox in pivotal PhIII |date=19 December 2011 }} Additionally, Tedizolid was shown to have fewer treatment-related side effects than linezolid and significantly fewer GI side effects.{{cite web |title=Trius Therapeutics' Tedizolid has Blockbuster Potential for MRSA Infections (TSRX, $5.05) |url=http://smithonstocks.com/component/content/article/3/261-trius-therapeuticsarsquo-tedizolid-has-blockbuster-potential-for-mrsa-infections-tsrx-505 |website=smithonstocks.com |access-date=28 May 2023 |archive-url=https://web.archive.org/web/20120909210529/http://smithonstocks.com/component/content/article/3/261-trius-therapeuticsarsquo-tedizolid-has-blockbuster-potential-for-mrsa-infections-tsrx-505 |archive-date=September 9, 2012 |language=en}}

Trius was planning the second Phase 2 trial and expects to report results around the end of Q1 2013 and planned to submit an NDA to the FDA for the drug in the second half of 2013.{{cite news|last=Darcé|first=Keith|title=Trius grows as lead antibiotic moves forward|url=http://www.utsandiego.com/news/2011/oct/31/trius-grows-lead-antibiotic-moves-forward/|accessdate=5 September 2012|newspaper=San Diego Union-Tribune|date=31 October 2011}}

Tedizolid was approved by the US Food and Drug Administration on June 20, 2014.

The firm was acquired by Cubist Pharmaceuticals at the end of July 2013 in a deal worth $1.6 billion. This fee also included the purchase of Optimer Pharmaceuticals.{{cite news| url= https://www.reuters.com/article/us-cubist-deal-idUSBRE96T1BI20130731| title= Cubist to pay up to $1.6 billion for two antibiotics makers | author= Vrinda Manocha and Zeba Siddiqui | publisher=Reuters | date=30 July 2013}}

In February 2007 Trius was formed (formerly Rx3) in conjunction with a Series A financing.{{cite web|url=http://www.fiercebiotech.com/special-reports/emerging-drug-developer-trius-therapeutics|title=Emerging Drug Developer: Trius Therapeutics |date=28 March 2008 }} Trius completed an initial public offering in August 2010, raising $50 million.{{cite news|url=https://www.bloomberg.com/news/2010-08-03/trius-therapeutics-initial-offer-raises-50-million-update2-.html | work=Bloomberg | first1=Kristen | last1=Scholer | first2=Lee | last2=Spears | title=Trius Therapeutics Initial Offer Raises $50 Million | date=3 August 2010}} Its stock was added to the NASDAQ Biotechnology Index in 2012.{{cite web|title=Semi-Annual Changes to the NASDAQ Biotechnology Index|url=http://www.marketwatch.com/story/semi-annual-changes-to-the-nasdaq-biotechnology-index-2012-05-14|publisher=MarketWatch|accessdate=27 July 2012}}

In 2008 the company received a $28 million contract from the National Institute of Allergy and Infectious Diseases a component of the National Institutes of Health, to develop antibiotics against gram-negative infections. The work included a collaboration with the Lawrence Livermore National Laboratory to help identify antibiotics against gram-negative infections and bioterrorism.{{cite news|last=Timmermeyer|first=Luke|title=Trius Therapeutics Wins $28M Contract From NIH For Bioterror Antibiotics|url=http://www.xconomy.com/san-diego/2008/10/22/trius-therapeutics-wins-28m-contract-from-nih-for-bioterror-antibiotics/|accessdate=5 September 2012|newspaper=Xconomy|date=22 October 2008}} Trius was awarded a contract by Lawrence Livermore National Laboratory in 2011 for $3 million.{{cite web |title=Trius Therapeutics, Inc. Secures Third Government Contract To Develop Antibiotics |url=https://www.reuters.com/finance/stocks/TSRX.O/key-developments/article/2291312 |website=www.reuters.com |publisher=Reuters |access-date=28 May 2023 |archive-url=https://web.archive.org/web/20120420044649/https://www.reuters.com/finance/stocks/TSRX.O/key-developments/article/2291312 |archive-date=2012-04-20 |language=en |date=15 Apr 2011}} In 2011 Bayer acquired the exclusive rights to Trius' antibiotic tedizolid in certain areas in Asia, Africa, the Middle East, and Latin America.{{cite news|last=Conover|first=Damien|title=Premium Articles 5 Big Pharma Opportunities in Emerging Markets|url=http://www.morningstar.co.uk/uk/news/70333/5-Big-Pharma-Opportunities-in-Emerging-Markets.aspx|accessdate=5 September 2012|newspaper=Morning Start|date=3 September 2012}} The deal was reported as being worth $94 million.{{cite news|last=Darcé|first=Keith|title=Trius signs $94 million licensing deal for lead antibiotic|url=http://www.utsandiego.com/news/2011/jul/27/trius-signs-94-million-licensing-deal-lead-antibio/|accessdate=5 September 2012|newspaper=San Diego Union-Tribune|date=27 July 2012}}

Trius was founded by the last Chief Financial Officer John Schmid and Chief Scientific Officer John Finn.{{cite news|title=Trius Therapeutics Inc|url=https://www.bloomberg.com/quote/TSRX:US/profile|publisher=Bloomberg News|accessdate=5 September 2012}} Other executives included Chief Executive Officer Jeffrey Stein, Chief Medical Officer Philippe Prokocimer, Chief Commercial Officer Craig Thompson,{{cite web|url=https://www.sec.gov/Archives/edgar/data/1356857/000119312512115086/d270282d10k.htm|title=Form 10-K }} and Chief Development Officer Ken Bartizal.{{cite web|url=https://www.sec.gov/Archives/edgar/data/1356857/000119312512115086/d270282d10k.htm|title=Form 10-K }} The Chairman of the Board is David Kabakoff.{{cite web|title=Trius Therapeutics, Inc. Executives|url=http://www.hoovers.com/company/Trius_Therapeutics_Inc/rjrcsji-1-1nji3h-1njhtz.html|publisher=Hoover's|accessdate=5 September 2012}} The company today has 83 full-time employees.{{cite news|title=Company Overview of Trius Therapeutics, Inc.|url=http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=22562481|archive-url=https://web.archive.org/web/20090731134633/http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=22562481|url-status=dead|archive-date=July 31, 2009|accessdate=5 September 2012|newspaper=Businessweek}}

{{reflist}}

• {{official website|http://www.triusrx.com/index.php|Trius Therapeutics}}

Category:Biotechnology companies of the United States

Category:American companies established in 2004

Category:2004 establishments in California

Category:Health care companies based in California

Category:Technology companies based in San Diego

Category:Health care companies established in 2004

Category:Technology companies established in 2004